Advocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real‐World Multicenter Study
MedComm · 2026-08 · 7 (8)
DOI: 10.1002/mco2.70909 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 14.08.2026. Verfasst von Peiyu Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Controversies persist regarding the optimal regimens of neoadjuvant and adjuvant therapies for locally advanced esophageal squamous cell carcinoma (ESCC). This real‐world cohort study aimed to compare the efficacy of neoadjuvant chemotherapy (NCT), chemoradiotherapy (NCRT), and chemoimmunotherapy (NCIT), and to clarify the survival contributions of adjuvant strategies. We retrospectively enrolled 1818 ESCC patients across four high‐volume Chinese medical centers. After propensity score matching, pathological tumor response and tumor downstaging followed the hierarchy NCRT > NCIT > NCT, yet no significant differences were detected in overall survival (OS) or progression‐free survival (PFS). Subgroup analyses revealed superior OS benefits of NCIT in never‑smokers, nondrinkers, and patients with clinical N2–3 disease compared with NCT. While NCRT showed greater PFS benefit than NCIT as clinical T stage advanced, its OS advantage was restricted to obese individuals. Adjuvant immunotherapy extended PFS for patients receiving prior NCIT, whereas adjuvant chemotherapy delivered survival benefits to those with pathological lymph node metastasis. We constructed optimal treatment rule (OTR) decision trees with moderate‐to‐good predictive capacity to guide selection of neoadjuvant and adjuvant therapies based on survival benefit. These results highlight the necessity of precision perioperative therapy for ESCC. The established OTR decision trees can support individualized clinical decision‐making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China.
- Department of Thoracic Surgical Oncology National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
- Department of Thoracic Surgery The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital Zhengzhou Henan China.
- Department of Thoracic Surgery Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University Taiyuan Shanxi Ch…
ORCID-Profile: Peiyu Wang, Xiangnan Li, Yin Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, P., Wei, X., Yu, Y., Zhao, Z., Ge, Q., Lian, J., Xing, W., Li, X., & Li, Y. (2026). Advocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real‐World Multicenter Study. MedComm, 7(8). https://doi.org/10.1002/mco2.70909
Vancouver
Wang P, Wei X, Yu Y, Zhao Z, Ge Q, Lian J, et al. Advocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real‐World Multicenter Study. MedComm. 2026;7(8). doi:10.1002/mco2.70909
BibTeX
@article{Wang2026,
author = {Wang, Peiyu and Wei, Xiufeng and Yu, Yongkui and Zhao, Zhiqian and Ge, Qiuchen and Lian, Jianhong and Xing, Wenqun and Li, Xiangnan and Li, Yin},
title = {Advocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real‐World Multicenter Study},
journal = {MedComm},
year = {2026},
volume = {7},
number = {8},
doi = {10.1002/mco2.70909}
}
EUVIMED